Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
escitalopram + memantine
- Development stage
- Unknown
- Lead developer
- Lundbeck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Escitalopram + memantine is a combination of two small molecule drugs used in clinical research for the treatment of major depressive disorder (MDD) in older adults with subjective memory complaints. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels in the brain by inhibiting its reuptake, thereby improving mood and alleviating symptoms of depression. Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist that modulates glutamatergic neurotransmission and is primarily used to treat moderate-to-severe Alzheimer's disease due to its neuroprotective effects. The combination has been studied for its potential to improve both depressive symptoms and cognitive function in geriatric patients, showing greater improvements in executive functioning, delayed recall, gray matter volume, and cortical thickness compared to escitalopram alone[1][2][3][5].
- Other names
- escitalopram and memantineESC/MEM
02
Targets
SERT (Sodium-dependent serotonin transporter)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on escitalopram + memantine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on escitalopram + memantine.